Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells

Diana Cervantes-Madrid, Joanna Szydzik, Dan Emil Lind, Marcus Borenäs, Mats Bemark, Jean Cui, Ruth Helen Palmer, Bengt Hallberg

Open source

DOI
10.1038/s41598-019-55060-7
Published
2019-12-18
Container
Scientific Reports
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-019-55060-7,
  title = {Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells},
  author = {Diana Cervantes-Madrid and Joanna Szydzik and Dan Emil Lind and Marcus Borenäs and Mats Bemark and Jean Cui and Ruth Helen Palmer and Bengt Hallberg},
  year = {2019},
  journal = {Scientific Reports},
  doi = {10.1038/s41598-019-55060-7},
  url = {https://doi.org/10.1038/s41598-019-55060-7}
}

RIS

TY  - JOUR
TI  - Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
AU  - Diana Cervantes-Madrid
AU  - Joanna Szydzik
AU  - Dan Emil Lind
AU  - Marcus Borenäs
AU  - Mats Bemark
AU  - Jean Cui
AU  - Ruth Helen Palmer
AU  - Bengt Hallberg
PY  - 2019
JO  - Scientific Reports
DO  - 10.1038/s41598-019-55060-7
UR  - https://doi.org/10.1038/s41598-019-55060-7
ER  - 

APA

Cervantes-Madrid, D., Szydzik, J., Lind, D. E., Borenäs, M., Bemark, M., Cui, J., Palmer, R. H., & Hallberg, B. (2019). Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. Scientific Reports. https://doi.org/10.1038/s41598-019-55060-7

Source records